Showing Results for: “Contact ”

Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National Kidney Month Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD). The kick-off for this expanded effort coincides with National Kidney Month, a time when both organizations bolster

Leading Diabetes Scientific Sessions Meeting Will Present Groundbreaking Data on Key Topics Including: Obesity, Technology, AI Health and the Latest in Diabetes Innovation From June 21–24, the American Diabetes Association® (ADA) will host the 84th Scientific Sessions in Orlando, FL. The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The hybrid meeting will feature the latest scientific findings in diabetes, including more than 200 sessions and 2,000

Research Presented at the ADA’s Scientific Sessions Highlights Need to Address Health Equity to Improve Diabetes Management and Outcomes Today, two studies provide evidence that social determinants of health account for disparities in health outcomes related to diabetes. Both studies were released as poster presentations at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA. This research comes at a time when individuals with lower socioeconomic status are more likely to develop diabetes, experience more complications, and die sooner than those with a

Leading Diabetes Scientific Sessions Meeting Brings Together Researchers From Around the World With Hybrid Format Today, the American Diabetes Association ® (ADA) kicks off the 82nd Scientific Sessions in New Orleans, LA. The ADA’s Scientific Sessions is the world’s premier meeting in diabetes with a broader reach than ever with hybrid options for attendees. The meeting will take part live and virtually from around the globe today, June 3, through June 7 at the Ernest N. Morial Convention Center, presenting the latest cutting-edge advances in diabetes research, prevention, and care. This year

Update on SCORED and SOLOIST trials shows reduction in cardiovascular events and stroke using glucose-lowering agents Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 (SGLT2) and sodium-glucose transport protein 1 (SGLT1) in reducing heart failure, heart attack, and stroke—major problems in people with diabetes. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with diabetes are at an increased risk of life-threatening

Expanded results from the first-of-its-kind clinical trial explores the use of SGLT2 inhibitor for COVID-19 patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19. Additional findings from the trial were presented today at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with cardiometabolic risk factors, including

Premier Diabetes Meeting to Feature Cutting-Edge Data on Obesity, Emerging Technologies, the Innovation Challenge, and the Latest Advances in Diabetes Treatment From June 20–23, the American Diabetes Association ® (ADA) will host the 85 th Scientific Sessions in Chicago. The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 attendees from around the globe to share cutting-edge scientific discoveries and advancements in diabetes care and innovation. This year’s Scientific Sessions will commemorate the extraordinary advancements in diabetes knowledge

NIDDK study continues to look at possible factors that lead to the development of the diseases in children New results and information surrounding potential “triggers” of the autoimmune process leading to type 1 diabetes (T1D) and how they interact with genetic factors in children at-risk for developing the disease were highlighted in the “Update from the TEDDY Study” symposium today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. Similar evidence for celiac disease is also being accumulated through the large international study program. The data The

Learn how to develop a written accommodations and care plan under federal disability law to meet your child's diabetes needs. Get legal protections & state law insights.

Safe at School: Colorado